Preclinical News and Research

RSS
Omeros fourth quarter net loss increases to $7.2 million

Omeros fourth quarter net loss increases to $7.2 million

15 Mar 2011
CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial

CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial

15 Mar 2011
ShangPharma fourth quarter net revenues increase 29.4% to $25.6 million

ShangPharma fourth quarter net revenues increase 29.4% to $25.6 million

15 Mar 2011
InhibOx and COSMIC discoveries align to deliver full service drug discovery offering

InhibOx and COSMIC discoveries align to deliver full service drug discovery offering

15 Mar 2011
New study: Two peptide agent combination might block tumor growth

New study: Two peptide agent combination might block tumor growth

15 Mar 2011
Positive results from azide drug-loaded Emulsiphan preclinical toxicity study

Positive results from azide drug-loaded Emulsiphan preclinical toxicity study

14 Mar 2011
European Patent Office grants ProtAffin key patent for CellJammer discovery technology

European Patent Office grants ProtAffin key patent for CellJammer discovery technology

14 Mar 2011
SOM Biotech closes first financing round and files patent application

SOM Biotech closes first financing round and files patent application

14 Mar 2011
Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

11 Mar 2011
Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

11 Mar 2011
American Botanical Council honors excellence in herbal medicine

American Botanical Council honors excellence in herbal medicine

11 Mar 2011
NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

11 Mar 2011
Oncothyreon 2010 net loss decreases to 15.6 million

Oncothyreon 2010 net loss decreases to 15.6 million

10 Mar 2011
Idera reports $6.0 million net loss for fourth quarter 2010

Idera reports $6.0 million net loss for fourth quarter 2010

10 Mar 2011
Positive results from Creabilis CT327 Phase IIa study in patients with psoriasis vulgaris

Positive results from Creabilis CT327 Phase IIa study in patients with psoriasis vulgaris

10 Mar 2011
Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

10 Mar 2011
CTI announces final pixantrone clinical trial design for treatment of DLBCL

CTI announces final pixantrone clinical trial design for treatment of DLBCL

10 Mar 2011
Experimental drug effectively shuts off MCL1 gene and induces apoptosis

Experimental drug effectively shuts off MCL1 gene and induces apoptosis

10 Mar 2011
NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

9 Mar 2011
ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

9 Mar 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback